文献速递类风湿关节炎

老年起病类风湿关节炎进阶管理的启发性发现

Eye-openers for advanced management of elderly-onset rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

基于tREACH试验的多中心、分层、单盲、达标治疗管理研究,比较年轻起病(<45岁,n=119)、中年起病(45-65岁,n=208)和老年起病(>65岁,n=98)类风湿关节炎患者2年临床结局与患者报告结局。老年起病患者诊断时肿胀关节、侵蚀和合并症更多,但疾病活动度相似,且疼痛和疲劳较年轻患者更轻,需bDMARD比例更低(15% vs 30%和30%)。

要点

  • 老年起病RA诊断时肿胀关节、侵蚀和合并症更多,但疾病活动度与年轻起病者相似。
  • 达标治疗下2年bDMARD使用率:年轻起病30%、中年起病30%、老年起病15%。
  • 老年起病患者疼痛和疲劳较年轻起病者更轻,其他患者报告结局无临床相关差异。

核心结论

  • 尽管诊断时预后因素不利,在达标治疗管理下老年起病RA患者与年轻患者结局相似。
  • 值得注意的是,较少的老年起病RA患者需要bDMARD即可达到相同治疗目标。

研究设计与样本

  • tREACH试验为多中心、分层、单盲试验,采用达标治疗管理策略和固定用药方案。
  • 纳入所有RA患者,按诊断时起病年龄分为年轻起病RA(<45岁,n=119)、中年起病RA(45-65岁,n=208)和老年起病RA(>65岁,n=98)。
  • 采用混合模型比较随时间变化的临床结局和患者报告结局。

主要发现

  • 诊断时老年起病RA患者较年轻患者有更多肿胀关节、侵蚀和合并症。
  • 诊断时及随访期间各年龄组疾病活动度保持相似。
  • 随访2年后bDMARD使用率在年轻起病RA、中年起病RA和老年起病RA分别为30%、30%和15%。
  • 老年起病RA患者较年轻起病RA患者疼痛低1(95%CI 0.5-1.6)、疲劳低17.3 mm(95%CI 11.3-23.4)。
  • 老年起病RA患者较中年起病RA患者疼痛低0.6(95%CI 0.1-1)、疲劳低5.8 mm(95%CI 0.7-10.9)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate whether clinical outcomes and patient-reported outcomes (PROs) differ over 2 years based on the age of onset of RA. METHODS: All RA patients from the tREACH trial, a multicentre, stratified, single-blinded trial with a treat-to-target management approach and a fixed medication protocol were included. The age of disease onset was categorized into young-onset RA (YORA) (<45 years, n = 119), middle-aged onset RA (MORA) (45-65 years, n = 208) and elderly-onset RA (EORA) (>65 years, n = 98) at the time of diagnosis. Mixed models were used to compare clinical outcomes and PROs over time. The following PROs were included: pain (Numeric Rating Scale), fatigue (visual analogue scale), functional ability (HAQ-Disability Index, HAQ-DI), quality of life (European Quality of Life 5-Dimensions 3-Levels, EQ-5D-3L), and possible depression (Hospital Anxiety and Depression Scale-Depression, HADS-D) or anxiety disorder (HADS-Anxiety, HADS-A). RESULTS: At diagnosis, EORA patients had more swollen joints, erosions and comorbidities than younger patients. However, disease activity remained similar across age groups at diagnosis and over time. After 2 years of follow-up, bDMARD usage was 30%, 30% and 15% in YORA, MORA and EORA patients, respectively. EORA patients also experienced less pain and fatigue over time compared with YORA patients [1 (95% CI 0.5-1.6) and 17.3 mm (11.3-23.4) lower] and MORA patients [0.6 (0.1-1) and 5.8 mm (0.7-10.9) lower]. No other clinically relevant PRO differences were observed. CONCLUSION: Despite unfavourable prognostic factors at diagnosis, EORA patients have similar outcomes compared with their younger counterparts if a treat-to-target management approach is applied. Notably, fewer EORA patients required bDMARDs to reach the same treatment target.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Dag HH, Snoeck Henkemans SVJ, Looijen AEM, et al. Eye-openers for advanced management of elderly-onset rheumatoid arthritis. Rheumatology (Oxford). 2025. PMID: 40795771. doi:10.1093/rheumatology/keaf432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。